Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Intraperitoneal Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Peritoneal Carcinomatosis

NCT01443260 is registered in ClinicalTrials.gov with Genelux GmbH as lead sponsor.

NCT NCT01443260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01443260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Intraperitoneal Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Peritoneal Carcinomatosis
Lead sponsor
Genelux GmbH
Phase
Phase 1/2
Overall status
Completed
Start date
February 29, 2012
Completion date
September 30, 2014
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peritoneal carcinomatosis